Ana I. Ballesteros - Publications

Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 23, 2024

Pain in Long-Term Cancer Survivors: Prevalence and Impact in a Cohort Composed Mostly of Breast Cancer Survivors.

Journal: Cancers

Published: March 26, 2024

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.

Journal: Cancers

Published: May 13, 2022

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).

Journal: Breast (Edinburgh, Scotland)

Published: July 15, 2020

Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies.

Journal: Oncoimmunology

Published: November 16, 2019

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.

Journal: BMC genomics

Published: September 28, 2018

Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.

Journal: Melanoma research

Published: July 06, 2018

Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 21, 2018

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 05, 2017

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Journal: Anticancer research

Published: December 06, 2015

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 30, 2015

Use of bevacizumab as a first-line treatment for metastatic breast cancer.

Journal: Current oncology (Toronto, Ont.)

Published: April 25, 2015